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Stemcellresearchplaysanimportantroleinorthopedicregenerativemedicinetoday.Currentliteratureprovidesuswithpromising
results from animal research in the ﬁelds of bone, tendon, and cartilage repair. While early clinical results are already published
for bone and cartilage repair, the data about tendon repair is limited to animal studies. The success of these techniques remains
inconsistent in all three mentioned areas. This may be due to diﬀerent application techniques varying from simple mesenchymal
stem cell injection up to complex tissue engineering. However, the ideal carrier for the stem cells still remains controversial. This
paper aims to provide a better understanding of current basic research and clinical data concerning stem cell research in bone,
tendon, and cartilage repair. Furthermore, a focus is set on diﬀerent stem cell application techniques in tendon reconstruction,
cartilage repair, and ﬁlling of bone defects.
1.Introduction
Today great hope is set on regenerative medicine in all med-
ical ﬁelds. Leland Kaiser introduced the term “Regenerative
medicine” in 1992. He forecastedthat “a new branch of med-
icine will develop that attempts to change the course of
chronic diseases and in many instances will regenerate tired
and failing organ systems” [1]. Since then, scientists all over
the world try to develop cell-based approaches to regenerate
damaged tissues, or even substitute whole organs [2].
Of course, regenerative medicine has developed to be of
interest in orthopedics. There, great hope was set on regen-
erative medicine to develop alternative therapies for cartilage
damage,arthritis,largebonedefects,oratrophictendonrup-
tures during the last decade. These are all indications, which
are treatable only insuﬃciently with conventional implants
a n ds u r g i c a lp r o c e d u r e s[ 3–10]. Therefore, they frequently
result in decreased function of the musculoskeletal system or
even loss of patients’ mobility. In the worst case, the men-
tioned diseases even result in a loss of autonomy for the
patient. In consequence, this implies immense costs for the
health care systems all over the world.
In this review, we focus on application of stem cells in
regenerativemedicinefororthopedicindications.Wepresent
currentapproachesinstemcell-basedtherapyinorthopedics
and review recent successes in basic science and clinical
application of regenerative medicine approaches within the
ﬁeld.
2. Stem Cells
Stem cells are of particular interest in regenerative medicine.
They inhere several unique characteristics that distinguish
themfromothercelltypes.Stemcellsrepresentunspecialized
cells, which have the ability to diﬀerentiate into diﬀer-
ent adult cell types. Here, it is important to distinguish em-
bryonicstemcells,whicharetrulypluripotentfrommultipo-
tent adult stem cells. Embryonic stem cells (ESCs) are only
found in early developmental stages of the organism. They
represent the only cell type, which has the ability to renew
itself indeﬁnitely and is truly pluripotent. As a unique pre-
cursor cell, it can diﬀerentiate into cells of all three germ
layers [2]. In contrast, a variety of multipotent adult stem
cells exists in assumedly all tissues of the organism. They are2 Stem Cells International
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Figure 1: The two strategies of stem cell application in regenerative
medicine. Stem cells are either isolated from the patient (auto-
logous transplantation) or from other donors (allogenous trans-
plantation). The cells are expanded in vitro and either applied di-
rectly to the patient to substitute lost cells (“cell therapy”), or seed-
ed into 3 dimensional scaﬀolds (“Tissue engineering”) and diﬀer-
entiated into the demanded cell type. The composed artiﬁcial tissue
construct is subsequently implanted into patients’ tissue defect.
responsible for maintaining the integrity of the tissue they
reside in. Usually, these adult stem cells show limited diﬀer-
entiation potential to tissues of one germ layer [2].
The use of human ESCs as a resource for cell therapeutic
approaches is currently an intensively researched ﬁeld [11–
13].Fromalegalandethicalpointofview,researchinvolving
human embryonic cells is highly controversial and many
countries are reviewing their legislation. Besides the ethical
concerns, the use of embryonic stem cells is problematic, as
the application of allogenic pluripotent cells inheres a dis-
tinct oncogenic potential that currently forbids the applica-
tion in patients.
TheworkofTakahashiandYamanakain2006hasopened
newperspectivesinregenerativemedicine.Hisgroupwasthe
ﬁrst to demonstrate successful dediﬀerentiation of somatic
cells into a pluripotent ESC-like status by transfection with
four embryonic transcription factors [14]. The so-called in-
duced pluripotent stem cells (iPS cells) provide the possi-
bility of autologous therapy with pluripotent and easily ac-
cessiblecellsinthefuture.Besidethegreatpotentialthistech-
nique undoubtedly represents, it bears some essential safety
problemswhicharecurrentlyfarfrombeingsolved.AsESCs,
these cells inhere a high oncogenic potential which cur-
rently forbids application in patients. If they are injected
in an undiﬀerentiated state, they cause teratomas, and mice
generated from iPS cells show high rates of tumors. This
oncogenicity may be due to the transcription factors used
for dediﬀerentiation which are known to be oncogenes, due
to the insuﬃcient epigenetic remodeling or due to the on-
cogenic retroviruses used for transfection [15].
The use of adult stem cells raises less ethical concerns
and has proved to be much safer than pluripotent stem cells.
In addition, these cells have further advantages compared to
ESCs, for example, a use for autologous cell therapies, using
patients’ own cells to reduce possible immune responses,
is easier to realize. Nonetheless, the limited diﬀerentiation
potential of adult stem cells narrows their applicability. Typi-
cally, adult stem cells can diﬀerentiate into the cell types of
the tissue in which they reside. Mesenchymal stem cells have
been found to be the most promising candidates, as they
showgooddiﬀerentiationpotentialtowardscartilage,tendon
and bone cells. They can be isolated from a number of mes-
enchymal tissues as for example bone marrow, fat, synovial
membrane, periosteum, and others [16]. Interestingly, these
mesenchymal stem cells have been found to diﬀer regard-
ing their diﬀerentiation potential dependent on their tissue
source [17].
As ethical and safety concerns currently forbid applica-
tion of iPS cells and ESCs in patients [2, 18], we will focus on
adult mesenchymal stem cells within the rest of the paper.
3. Application of Mesenchymal Stem Cells in
Regenerative Medicine
Regenerative medicine mainly includes two diﬀerent strate-
gies of cell-based therapy. In the ﬁrst approach, cells are
applied to substitute damaged cells within a tissue to
reconstituteitsintegrityandfunction.Duringthisprocedure
called “cell therapy” a cell suspension is simply injected into
the damaged tissue or into the blood circulation. The second
approach called “tissue engineering” is more complex. Here,
cells are combined with a three dimensional matrix to com-
pose a tissue-like construct to substitute lost parts of the
tissue, or even whole organs (Figure 1)[ 2].
One of the most successful examples in “cell therapy” is
the transplantation of hematopoietic stem cells. This pro-
cedure has now been practiced for decades to treat serious
hematological diseases. For transplantation of bone marrow,
hematopoietic stem cells are injected into the blood cir-
culation of the recipient. Interestingly, they ﬁnd their way
to the bone marrow by a phenomenon termed “homing.”
Chemokines were found to play a key role in homing of
hematopoietic stem cells [19–21].
Several experiments have proven the ability of homing to
injuredtissueforseveraltypesofstemcells.Inanimalmodels
of hepatic intoxication, partial hepatectomy, myocardial
infarction, nephropathy, cerebral ischemia, lung injury, lung
ﬁbrosis, and local irradiation, stem cells enriched in injured
tissue and partially diﬀerentiated into tissue-speciﬁc cell
types after systemic injection [22–38]. Cell therapy with
systemically injected mesenchymal stem cells was also per-
formedinhumans,showingbeneﬁcialeﬀectsingraft-versus-
host disease or osteogenesis imperfecta [39, 40].
However, cell therapy alone is not suﬃcient to regenerate
large tissue defects or even replace whole organs. Therefore,
the approach of “tissue engineering” is the more promising
strategy. In the process, tissue-speciﬁc cells are seeded on a
scaﬀoldimitatingthearchitectureofthetissue-speciﬁcextra-
cellular matrix. In the last decade, basic science has made
great advantages in tissue engineering research, resulting in
in vitro composition of multiple diﬀerent functional tissue
constructs [41]. Nonetheless, tissue engineering therapy has
barely reached the patient [42]. The reason for the modest
entering of tissue engineering methods into the clinic is
the yet unsolved problem of vascularization [43]. Thus, anStem Cells International 3
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Figure 2: Stem cells participate in tissue regeneration in diﬀerent
ways. They directly diﬀerentiate into tissue-speciﬁc cells and thus
substitute damaged or lost cells (A). They indirectly inﬂuence tissue
regeneration by secretion of soluble factors. Here they promote
vascularization, cell proliferation, diﬀerentiation within the tissue
(B) and modulate inﬂammatory processes (C).
intact vascular network is a prerequisite to realize tissue con-
structs of more than 400μm in diameter [44]. In the last
decade many scientists in the ﬁeld of tissue engineering have
focused on solving the problem of vascularization. However,
all eﬀorts proving applicability for tissue engineering of large
solid tissues or even whole organs in humans have failed
so far (for paper see [43]). Nonetheless, tissue engineering
was already successfully used in patients to substitute either
hollow organs with limited wall diameter (trachea, bladder)
or avascular tissues as cartilage [45–47]. In these cases, the
diﬀusion trajectory is suﬃcient to maintain cell survival.
4. Participation of Mesenchymal Stem Cellsin
Tissue Regeneration
Mesenchymal stem cells have the ability to migrate chemo-
tactically to tissues showing inﬂammation and injury in the
organism [48]. Besides their unique ability to diﬀerentiate
into diﬀerent cell types, mesenchymal stem cells were found
to secrete a variety of cytokines, showing anti-inﬂammatory
activity and create an anabolic microenvironment [17]. Fur-
thermore, direct cell-cell contact immunomodulation has
alsobeenshown.Thus,theyparticipateinregenerationofin-
juredtissuesindiﬀerentways.Ononehand,theydirectlydif-
ferentiate into tissue-speciﬁc cells and thus substitute dam-
agedorlostcells.Ontheotherhand,theyindirectlyinﬂuence
tissue regeneration by secretion of soluble factors. Thirdly,
they are able to modulate the inﬂammatory response. Thus,
theycanpromotevascularization,cellproliferation,diﬀeren-
tiation and modulate an inﬂammatory process (Figure 2).
Indeed, there is evidence for all mentioned activities
of MSCs in tissue regeneration from in vitro and in vivo
experiments. The diﬀerentiation potential of MSCs was
extensively studied in vitro. The cells were found to inhere
the potential of multilineage diﬀerentiation towards possibly
all kinds of mesenchymal cells such as cartilage, bone,
tendon, and fat cells, and ﬁbroblasts [69]. Excitingly, further
studies revealed that diﬀerentiation capacity of MSCs seems
not to be restricted to cells belonging to the mesenchymal
lineage. They were shown to be able to diﬀerentiate towards
cells from other germinal layers, as for example, neurons,
glia cells, cardiomyocytes, endothelial cells and hepatocytes
[70–73]. In vivo experiments and ﬁrst clinical applications
conﬁrmed the ability of MSCs to engraft within a variety of
injured tissues and diﬀerentiate into tissue-speciﬁc cells and
thus substitute lost cellular function [17, 74].
In many studies, beneﬁcial eﬀects appeared without any
detectable engraftment of the applied mesenchymal stem
cells to the damaged tissue, however. Moreover, MSC pro-
tein extracts and conditioned medium from MSC cultures
showed similar improvement of organ function in liver
disorders or heart ischemia [75, 76]. Further investigation of
MSCsrevealedthattheyreleaseparacrinefactorsforexample
IGF-1, HGF, VEGF, IGF-2, bFGF, or pre-microRNAs which
protect’s host cells, promote cell proliferation and enhance
angiogenesis[77,78].Thesepositiveeﬀectscouldpartiallybe
conﬁrmed in vivo, where MSCs activated expression of some
of the mentioned factors in the myocardium and promoted
angiogenesis [79]. Furthermore, MSCs secrete paracrine
factors which enhance lung function by regulating endothe-
lial and epithelial permeability, decreasing inﬂammation,
enhancing tissue repair, and inhibiting bacterial growth in
acute lung injury and acute respiratory distress syndrome
[80]. Beneﬁcial eﬀects of paracrine MSC signaling could
also be conﬁrmed in healing of cutaneous wounds [81].
The recently identiﬁed potential of paracrine MSC signaling
on damaged tissue even caused some authors call MSCs an
“injury drug store” [82].
Besides their mentioned diﬀerentiation potential and
their ability to promote tissue regeneration by secretion of
soluble factors, MSCs inhere extraordinary immunological
properties. There is increasing evidence that the cells them-
selvesarerelativelynonimmunogenic andtheycanbereadily
transplanted between diﬀerent individuals without initiating
an immune response [83]. Furthermore, they proved to
inhere anti-inﬂammatory and immunosuppressive capabil-
ity in vitro and in vivo, where they can modulate immune
responses on diﬀerent targets. They inhibit maturation of
immune cells, like helper T, cytotoxic T, dendritic, and
B cells. Additionally, cells express a number of cytokines
that can suppress inﬂammation, as for example TGF-beta1,
NO, prostaglandin-E2, HLA-G, hepatocyte growth factor,
and IL-10 [17]. The revealed anti-inﬂammatory eﬀects of
MSCs have opened a broad ﬁeld of possible applications in
transplantation and immune disorders. After conﬁrming the
anti-inﬂammatory eﬀectsin severalanimal models, ﬁrstpro-
mising clinical applications have succeeded. In these appli-
cations, MSCs showed beneﬁcial eﬀe c t so ng r a f tv e r s u sh o s t
disease after hematopoietic stem cell transplantation and on
Crohn’sdisease[84].However,ﬁrstresultsarepromisingand
the in vivo application seems to be rather safe, as no serious4 Stem Cells International
side eﬀects have been reported. Nonetheless, randomized
trials have to follow to conﬁrm these ﬁrst results.
5. ApplicationTechniques inOrthopedics
To diﬀerentiate between favorable application strategies the
aim of treatment is one important factor. As mentioned
before, MSCs have the potential to rebuild injured tissue but
also to secrete growth factors for enhancing tissue regenera-
tion. Depending on the underlying pathology, the treatment
strategies diﬀer considerably. In one patient a large tissue
defecthastobeﬁlledbymeansoftissueengineering,whereas
in another the substantial defect is bridged with residual
tissue of low quality and only an improvement of healing
environment is indicated.
Besides the direct injection in the surrounding tissue,
biomaterials are frequently used as carriers for drugs,
bioactive molecules and cells. These materials have to fulﬁll
some fundamental requirements. At ﬁrst they have to be im-
mune-compatible and nontoxic, whereas the degradation
process must neither release toxic substances nor tissue-toxic
concentrations of degradation products. For a later replace-
ment with regenerated tissue, bio-degradable materials are
important. The degradation velocity must be balanced as too
fast and too slow are both detrimental. Beside these quali-
ties, matrices formed from biomaterials must have distinct
properties with regard to the desired kind of tissue. The pre-
requisite of mechanical strength, bioactivity, and kinetics of
degradationanddrug/cellreleasesigniﬁcantlyvariesbetween
diﬀerent repair tissues. Besides the used biomaterials them-
selves, the 3-dimensional structures of scaﬀolds have great
inﬂuence on cell growth and diﬀerentiation. Scaﬀolds must
be highly porous with interconnected pores of a diameter of
at least 100μm to allow ingrowth of cells and vessels [85].
Pore sizes between 100 and 400μma r ei d e a l .
Despite the tissue engineering of bone, for which var-
ious inorganic materials, such as hydroxyapatite, calcium
phosphate, calcium carbonate, or glasses was tested, mainly
organic biomaterials have been investigated for scaﬀold for-
mation. These are either naturally derived, for example, col-
lagen, ﬁbrin, agarose, alginate, gelatin, silk or hyaluronic
acid, or produced synthetically. Synthetically produced
organic biomaterials are mainly polyhydroxyacids such as
polyglycolidesorpolylactides.Tocontrolkineticsofdegrada-
tion, recent studies were performed employing hydroxyl acid
copolymers. Thus, it has been tried to adapt kinetics of deg-
radation to those of tissue regeneration.
As these synthetic polymers often lack bioactivity, their
surface was modiﬁed to alter cell adhesion, migration, diﬀer-
entiation,andproliferationinrecentstudies.Thus,theywere
coated or copolymerized with bioactive materials or func-
tional groups were attached to the polymer chain before
scaﬀold fabrication [86–88]. Apart from surface modiﬁca-
tions with bioactive materials, scaﬀolds were coated directly
with cytokines to control proliferation and diﬀerentiation
of seeded cells [89]. Other authors describe the coating of
scaﬀolds with genetic vectors to perform transfection of cells
with diﬀerent growth factors [90]. Biomaterials for tissue
engineering can also carry drugs that prevent microbial
colonization or control ingrowth of scaﬀolds into the sur-
rounding tissue [91, 92].
5.1. Tendon Repair. Considering physiological properties of
tendon tissue, an application technique via scaﬀolds with
native extracellular matrix and the capability of cell seeding
and adhesion would be ideal [93]. Based on this hypothesis,
most of the current studies used scaﬀold application tech-
niques. The few studies which favored direct application
techniquesinjectedthesuspensionofMSCintobonetunnels
or on the bone surface before tendon reﬁxation to improve
tendon-to-bone healing [94, 95].
Scaﬀold application techniques for tendons can be
divided into gel suspensions, 3D scaﬀolds of solid tissue, and
hybrid techniques. Gel suspensions oﬀer a perfect 3D ﬁll-
ing of the defect, but the reduced stability in comparison
to stable matrices may result in loss of gel at the repair
site due to erosion. In a rabbit Achilles tendon model,
Chong et al. [96] used a mixture of ﬁbrin sealant and bone
marrow-derived mesenchymal stem cells. The ﬁbrin sealant
was injected into the tendon and the repair site was ad-
ditionally covered with the agent. Fibrin incorporates the
advantages of a clinical use over years including FDA appro-
val, bone marrow-derived mesenchymal stem cells remain
viable in ﬁbrin and published data indicate that ﬁbrin itself
has no eﬀect on tendon healing [97]. In this study no
diﬀerences between ﬁbrin and ﬁbrin with MSC could be
shown histologically. In the early healing phase (3 weeks),
signiﬁcantly improved biomechanical properties were docu-
mentedbutnotinsubsequenttimeperiods(6and12weeks).
In a rat rotator cuﬀ model, Gulotta et al. [98] also used MSC
in a ﬁbrin sealant and placed it between tendon and bone
before reﬁxation of the tendon. In this acute tendon repair
model they did not ﬁnd any signiﬁcant histological or bio-
mechanical diﬀerences after 2 or 4 weeks, respectively.
Noteworthy,thesamegrouprecentlysucceededinenhancing
tendon healing in the same rotator cuﬀ model, applying
transfected MSCs using the embryonic transcription factor
MT1-MMPandthetendontranscriptionfactorscleraxis[99,
100]. With a collagen gel, Awad et al. [101]p r e s e n t e daf u r -
ther gel-based application technique. They ﬁxed a collagen
g e lw i t hd i ﬀerent concentrations of MSC to suture material
and ﬁlled a defect in the rabbits’ patellar tendon. After 12
and 26 weeks, signiﬁcantly higher maximum stresses and
moduliweredocumentedcomparedtonaturalrepairtissues.
However, an adverse event was observed as there had been an
increased number of intratendinous ossiﬁcations (28%). In
comparison to the intact tendon only 25% of the ultimate
load was reached with MSC. Regarding all groups, cell
concentration had no signiﬁcant inﬂuence on the outcome.
This study group improved its application technique and
presented a hybrid technique (MSC in a gel-collagen sponge
composite) [102]. In the rabbit patellar tendon model,
the biomechanical properties and cellular alignment were
signiﬁcantly improved in the MSC group after 12 weeks. A
diﬀerent matrix is presented by Omae et al. in in vitro and
in vivo studies [103, 104]. Xenotendon slices with a thickness
of 50μm were decellularized and seeded with bone marrow
stromal cells. The ﬁrst results of the bundled construct inStem Cells International 5
a patellar tendon rat model showed a survival of the stromal
cells in all layers. In vivo results with MSC have not been
published yet but the approach is promising.
In conclusion, the application of MSC in tendon repair
shows promising but inhomogenous results in animal mod-
els. Current in vivo data favor the culture of MSC into
a tissue-engineered construct, with the advantage of pri-
mary stability and allowing the cells to produce their own
extracellularmatrix.Butthereisnoconsensusabouttheideal
carrier construct. Clinical data are not yet available for MSC
application in tendon repair.
5.2. Cartilage. Besides autograft transplantation and autolo-
gous chondrocyte transplantation, current therapeutic con-
cepts of cartilage defects include the recruitment of MSC.
Drilling, abrasion, or microfracturing of the subchondral
bone aims at the recruitment of MSC from the subchondral
bone to stimulate the formation of cartilage repair tissue.
In experimental and clinical studies of these standard
techniques, a nonhyaline cartilage with high proportions of
ﬁbrous elements and inferior functionality has been found
[105].
For autologous cartilage repair various two- and three-
dimensional constructs are available. Most of the matrices
consist of natural polysaccharides and proteins, such as
alginate and collagen. Furthermore, synthetic polymers are
also available for example, polyethylene glycol (PEG) or
polylactic acid (PLA). Successful outcome of a stem cell-
based cartilage tissue engineering also depends on the design
of extracellular matrix for a proper diﬀerentiation of MSCs
into chondrocytes [106]. The most important property,
namely, mechanical stability, to provide appropriate cell-
matrix interactions to stimulate tissue growth and capability
of functional tissue growth. The ideal matrix has suﬃcient
strength to protect the cells from axial load and shear forces,
is highly adhesive to remain stable in the repair site and pos-
sesses enough porosity to allow nutrient and diﬀerentiation
factors to diﬀuse through it. Currently, a large number of in
vitro studies focus on the optimal three-dimensional matrix.
Increasingly innovative matrices are tested in in vivo
animal models. For example, Shaﬁee et al. [107]p e r f o r m e d
MSC-based cartilage repair in a rabbit model with full-
thicknesscartilagedefects.Theyusedpoly(vinylalcohol)/po-
lycaprolactone (PVA/PCL) nanoﬁbers as matrix which
showed a support of MSC proliferation and chondrogenic
diﬀerentiation in vitro. The animals treated with MSC
showed an improved healing of the defects compared with
the untreated control. Tay et al. [108] used alginate-em-
bedded MSC for the repair of focal cartilage defects in a
rabbit model. They compared the macroscopic and histo-
logical results of MSC versus autologous chondrocyte trans-
plantation 6 months postoperatively. MSCs had a similar
eﬀectiveness as chondrocyte transplantation, MSC even
showed a signiﬁcantly better macroscopic score. Both treat-
ments resulted in superior tissue regeneration compared
with untreated control defects. These promising results from
the laboratory resulted in the ﬁrst clinical studies about car-
tilage repair with support of MSC. The earliest data are
case series of Wakitani et al. [109, 110]. They performed a
bone marrow aspiration from the iliac crest and the MSC
were expanded in culture. Four weeks later, the MSC were
implanted using a collagen gel and the defect was addition-
allycovered with a periosteal ﬂap. The authors describe satis-
fying clinical and macroscopic results, but the small number
of patients, the retrospective study design and the miss-
ing control has to be taken into consideration. Nejadnik
et al. [111] performed a matched pair analysis of 36 pa-
tients in each group who underwent autologous cartilage
transplantation or implantation of MSC. The postoperative
followup after 24 months showed no signiﬁcant diﬀerence of
diﬀerent functional knee scores between the groups.
In the treatment of osteochondral lesions, the group of
Budaetal.[66,112]publishedclinicalresultsoflesionsinthe
femur condyle and the talus. In the talus group, MSC were
taken from the iliac crest and incubated with a hyaluronic
acid membrane (n = 25) or collagen powder (n = 23)
before implantation in the defect in a single step procedure.
48 patients were examined clinically and radiologically
after an average of 29 months postoperatively. The clinical
scores revealed a signiﬁcant improvement compared to post-
operativescoreswhereasintheMRIandhistologyofsecond-
look arthroscopies none showed complete hyaline cartilage.
In the 20 patients with MSC therapy of the femur condyle
satisfactory clinical results (IKDC 90.4 points) were also
reported after an average of 29 months postoperatively. The
MRI showed a satisfactory integration of the graft in 80% of
the patients. Instead of direct defect coverage, some groups
describe a simple intra-articular injection of MSC [113],
with the intention of the ability of homing of the MSC.
Centeno et al. report about an injection in a patient with
early osteoarthritis of the knee. In the MRI followup after
6 months, they revealed an increased cartilage volume com-
pared to point of time before injection.
In summary, all applications for clinical use are based
on very small case series. The MSC application technique
was adopted from the clinical experience of autologous
chondrocyte transplantation (ﬁbrin, collagen gel, periosteal
ﬂap). Before a clinical use can be recommended, basic re-
search to optimize application techniques, cell preparation,
andconcentrationareessential[114].Withimprovedknowl-
edge from basic studies further evaluation of the clinical po-
tential of MSC application has to be performed in larger ran-
domized controlled trials.
5.3. Bone. In bone, the main focus of regenerative medicine
approaches lies on atrophic non union and replacement
of lost bone tissue. Large bone defects are usually caused
by trauma, infection, or tumors, as atrophic nonunion are
usually caused by insuﬃcient blood supply, interposition
of soft tissue or consequence after infection. Current treat-
ment strategies include autologous bone grafts from the
iliac crest, which is actually the gold standard—and as sal-
vage procedures—autologous ﬁbula graft transfer and allo-
genic bone graft transplantation. However, all mentioned
techniques show limitations, as bone supply is limited,
autologous bone harvesting is accompanied with high rates
of morbidity and allogenic transplantation inheres the risk
of transmission of diseases or rejection [115, 116].6 Stem Cells International
Table 1: Clinical applications of mesenchymal stem cells in bone regeneration.
Author Diagnosis Application n patients Results
Treatment of nonunions
Connolly et al.
1991 [49]
Atrophic
pseudarthrosis
Percutaneous autologous bone
marrow injection 20 Healing capacity comparable to
autologous cancellous bone grafting
Garg et al.
1993 [50]
Nonunion in long
bones
Percutaneous autologous bone
marrow injection 20 17 out of 20 cases united in 5 months
Kettunen et al.
2002 [51]
Tibially delayed or
non-union
Percutaneous autologous bone
marrow injection 41 Appeared to be as eﬀective as open
techniques
Hernigou et al.
2005 [52]
Atrophic
pseudarthrosis
Percutaneous autologous bone
marrow injection 60
Application is eﬀective and safe Positive
correlation between number of
progenitor cells and callus volume
Goel et al.
2005 [53] Tibial non-union Percutaneous autologous bone
marrow injection 20 15 out of 20 patients showed bone union
Treatment of osteonecrosis
Hernigou and
Beaujean
2002 [54]
Osteonecrosis
femoral head
Injection of autologous bone
marrow concentrate
116
(189 hips)
Very good results in early stages Injection
of greater number of progenitor cells
transplanted had better outcomes
Gangji et al.
2004 [55]
Osteonecrosis
femoral head
Injection of autologous bone
marrow concentrate 13 (18 hips) Signiﬁcant reduction of pain, progression
and improvement of function
Hernigou et al.
2009 [56]
Osteonecrosis
femoral head
Injection of autologous bone
marrow concentrate
342
(534 hips)
High amount of progenitor cells as
predictor for successful outcome
Enhancing spinal fusions
Neen et al.
2006 [57] Spinal fusions
Autologous bone marrow aspirate
on hydroxyapatite-collagen
I-composite
50
Similar healing capacity as autologous
cancellous bone grafting in posterolateral
fusion Inferior results in interbody
fusions
Gan et al.
2008 [58] Spinal fusions Bone marrow concentrate on
tricalciumphosphate 41 After 34.5 months 95.1% cases showed
good spinal fusion
Filling bone cysts
Wright et al.
2008 [59] Simple bone cysts Intralesional injection of
autologous bone marrow aspirate 77 Inferior results compared to injection of
methylprednisolone
Park et al.
2008 [60] Simple bone cysts
Implantation of autologous bone
marrow aspirate implanted in
combination with either nonvital
allogenic bone graft or injected with
bone powder
20 (23 cysts)
Injection of bone marrow-bone powder
mix is eﬀective alternative to open
treatment
Zamzam et al.
2009 [61] Simple bone cysts Percutaneous autologous bone
marrow injection 28 Application is a safe and eﬀective
treatment
Filling of bone defects
Salama and
Weissman 1978
[62]
Diﬀerent bone
defects
Xenograft with bone marrow
aspirate 28 Results have been “most satisfactory”
J¨ ager et al.
2009 [63]
volumetric bone
deﬁciencies
local autologous bone
marrow/mesenchymal stem cell
injection
10 May be a promising alternative to
autogenous bone grafting
Marcacci et al.
2007 [64]
Large bone
diaphysis defect
autologous MSCs were expanded in
vitro and seeded on hydroxyapatite
scaﬀolds
4
Followup up to 7 years after surgery,
good integration of implant, no
secondary fractures
Various applications
Hendrich et al.
2009 [65]
various bone healing
disturbances Bone marrow concentrate 101 Autogenous bone marrow concentrate
application is safe
Giannini et al.
2009 [66]
Osteochondral
talus defects
arthroscopic-assisted injection of
autologous bone marrow aspirate 48 Functional improvement
Dallari et al.
2007 [67]
High tibial
osteotomy
Lyophilized bone chips with
platelets-enriched plasma with bone
marrow aspirate
33
Lyophilized bone chips with
platelets-enriched plasma with or without
bone marrow aspirate enhance healing
Kitoh et al.
2009 [68]
femoral and tibial
lengthenings
Application of MSC expanded in
vitro with PRP
28
(51 osteotomies)
No enhancement of bone healing by
MSC/PRPStem Cells International 7
Inthelasttwodecades,regenerativemedicineapproaches
have been extensively studied to improve bone healing, or
even generate functional bone tissue to substitute lost bone.
Many in vitro studies were performed to investigate applica-
bility of diﬀerent stem cell types for bone regeneration. Here,
promising capacity for diﬀerentiating towards bone cells,
enhancing bone healing and vascularization could be proven
for embryonic stem cells and diﬀerent adult mesenchymal
stem cells. However, due to the ethical and safety concerns
mentioned above, only adult stem cells are presently taken
into consideration for therapeutic applications [63]. Here,
mesenchymal stem cells presently seem to be the most
promising candidates for bone regeneration, due to their
excellent osteogenic diﬀerentiation capacity [69].
In vitro trials found out that MSC strongly promote
angiogenesis by paracrine factors after mechanical stimula-
tion,asoccurringduringfracturehealing[117],whichmakes
MSC more interesting for bone regeneration. This paracrine
enhancement of angiogenesis in bone regeneration could
also be conﬁrmed in animal models in vivo [118].
The capacity of mesenchymal stem cells for homing to
injured tissues known from other ﬁelds was also demon-
strated for fractures. Here, mesenchymal stem cells showed
migration towards the fracture site after systemic application
in a mouse model. The study further revealed that the
cells enriched there and participated in fracture healing by
paracrine induction of tissue healing, reduction of systemic
and local inﬂammation and diﬀerentiating into bone cells
[74]. However, the majority of the stem cells were trapped
in the lungs after systemic application, thus making local
application more practicable for bone regeneration [119].
Diﬀerent groups achieved to compose small bone-like
tissue constructs in vitro, by composing MSC with a variety
of diﬀerent biomaterials. Implanted into animals, several of
these constructs survived in vivo [120]. However, researchers
did not succeed in composing vital bone pieces in larger
volumes, or even whole bones. This is due to the diﬀusion
tract being larger than 200μm. Beyond 200μm, diﬀusion is
not suﬃcient for providing cells with oxygen and nutrients.
Therefore, functional vascularization is a prerequisite for
survival of such solid tissues. Up to now, the problem of
vascularization in tissue engineering is not yet solved, in-
hibiting the translation of tissue engineering methods into
the clinic [43].
Nonetheless, regenerative medicine for bone healing has
reachedthepatientinformofcelltherapyapproachestotreat
localized bone defects or systemic diseases of the skeleton
[39]. Here, autologous bone marrow or autologous mes-
enchymal stem cells was successfully implanted in a number
of patients to enhance fracture/osteotomy healing, ﬁll bone
defects, treat pseudarthrosis, bone cysts, osteonecrosis, or
enhance spinal fusion. Relevant clinical applications are
summarized in Table 1.
6. Conclusions
Current data provides a number of interesting approaches
to treat musculoskeletal pathologies with the support
of mesenchymal stem cells. But considering the limited,
partially only preclinical data we believe that a standardized
clinical application will take at least an additional 5 to 10
years.In order to realizethe fulltherapeutic potential of stem
cells, a number of open questions has to be to be answer-
ed. Besides the necessity of establishing further data about
native stem cell function and pathways, basic research in
the understanding of native tendon, bone, and cartilage re-
generation also has to be continued. Especially signal path-
ways have to be understood because single-MSC application
might be insuﬃcient or only partially suﬃcient without
the adequate signal for inducing tissue regeneration. The
regenerated tissue also has to provide the appropriate 3-
dimensional structure including production of extracellular
matrix and biomechanical behavior according to native
tissue. Therefore, tissue engineering will play an important
role in the next years. In the near future, an interdisciplinary
approach with biologists, bioengineers, and clinicians will be
essential to achieve the clinical application of mesenchymal
stem cells.
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